Gujarat Kidney And Superspeciality Limited conducted a board meeting on March 19, 2026, addressing several important corporate governance matters and making key appointments for the Financial Year 2025-26. The meeting, held at the company's registered office from 05:15 P.M. to 06:15 P.M., resulted in significant decisions regarding auditor appointments, postal ballot approval, and ratification of financial results.

Key Board Decisions

The board approved multiple critical appointments and corporate actions during the meeting:

Auditor Appointments

Secretarial Auditor Profile: Mr. Dharmendra Bhaliya brings substantial expertise as an Associate member of the Institute of Company Secretaries of India (ICSI). He holds a master's degree in commerce and is a law graduate, currently working as a Practicing Company Secretary. His experience spans approximately 5 years in corporate laws including the Companies Act 2013, SEBI Act and regulations, and the Foreign Exchange Management Act 1999 (FEMA). He maintains a valid peer review certificate from ICSI.

Internal Auditor Profile: Mr. Siddharth Atulbhai Shah serves as an Associate member of the Institute of Chartered Accountants of India (ICAI) with around 7 years of experience in Assurance, Internal Audit, IFC Forensic & Fraud Risk. His professional certifications include Forensic Accounting & Fraud Detection (ICAI), Alternative Dispute Resolution (ADR) covering Arbitration, Mediation & Conciliation, and Concurrent Bank Audit Certification (ICAI).

Q2 FY25 Financial Performance

The company's Q2 FY25 financial results, which were ratified during this meeting, demonstrate solid operational performance across both standalone and consolidated metrics.

Standalone Results (Q2 FY25):

Consolidated Results (Q2 FY25):

Regulatory Compliance

The board addressed a compliance matter regarding the February 14, 2026 meeting, where financial results were discussed and approved but not formally recorded due to misunderstanding about SEBI (LODR) Regulations applicability following the company's listing on December 30, 2025. The board ratified these actions and resubmitted the financial results with corrections to typographical errors via letter dated March 13, 2026.

Corporate Structure

The consolidated results include performance from the company's subsidiaries and entities under control: Gujarat Surgical Hospital, Surya Hospital and ICU, and Raj Palmland Hospital Private Limited. This diversified healthcare portfolio contributed to the stronger consolidated revenue performance compared to standalone operations.

The company continues to focus on its primary business segment of healthcare services, with the board ensuring proper governance structures are in place through these auditor appointments and regulatory compliance measures.

Gujarat Kidney And Super Speciality Limited has released its unaudited financial results for the second quarter and half-year ended September 30, 2025. The Vadodara-based healthcare company reported mixed performance with quarterly revenue declining while half-yearly figures showed growth momentum.

Standalone Financial Performance

The company's standalone operations for Q2FY26 showed a revenue decline compared to the previous year. Key financial metrics demonstrate the challenging operating environment during the quarter.

Despite revenue growth of 2.47%, the company faced margin pressure with net profit declining significantly. Total expenses increased to ₹653.33 lacs from ₹545.06 lacs in Q2FY25, representing a 19.86% rise that outpaced revenue growth.

Half-Year Performance Shows Recovery

The half-year results for the period ended September 30, 2025, presented a more positive outlook with substantial growth across key metrics.

The six-month performance indicates the company's resilience and ability to generate consistent growth over longer periods, with revenue increasing by nearly 13% year-on-year.

Consolidated Results Outperform Standalone

The consolidated financial results, which include subsidiaries Gujarat Surgical Hospital, Surya Hospital and ICU, and Raj Palmland Hospital Private Limited, showed stronger performance metrics.

The consolidated revenue growth of 37.40% demonstrates the company's successful expansion strategy through its subsidiary network, though profitability remained under pressure.

Financial Position and Cash Flow

The company's balance sheet as of September 30, 2025, reflects a strengthened asset base with total assets increasing to ₹6,694.02 lacs from ₹4,907.23 lacs as of March 31, 2025. Current assets grew significantly to ₹3,763.26 lacs, primarily driven by increased trade receivables of ₹1,862.59 lacs and other current assets of ₹1,473.21 lacs.

Cash flow from operating activities showed negative ₹823.18 lacs for H1FY26 compared to positive ₹294.13 lacs in H1FY25, indicating working capital challenges. However, financing activities generated ₹974.04 lacs, primarily through short-term borrowings of ₹1,087.73 lacs.

Regulatory Compliance and Audit

The financial results were reviewed by statutory auditors Y.M. Shah & Co., who issued unmodified limited review reports for both standalone and consolidated results. The company's audit committee reviewed and recommended the results, which were subsequently approved by the Board of Directors on February 14, 2026.

The company operates in the healthcare sector with NABH accreditation and maintains its registered office at Plot No.1, City Survey No 1537/A, Gokak Mill Compound, Jetalpur Road, Alkapuri, Vadodara - 390020, Gujarat.